Anti-CD33 CAR-NK cell therapy (PersonGen Biomedicine)

N/A

Report date: 2022/08/29 15:41:01

Base Information

Drug NameAnti-CD33 CAR-NK cell therapy (PersonGen Biomedicine)
Drug Alias NameAnti-CD33 chimeric antigen receptor natural killer cellsAnti-CD33 chimeric antigen receptor natural killer92 cellsAnti-CD33 CAR-NK92 cellsAnti-CD33 chimeric antigen receptor natural killer cell therapyAnti-CD33 CAR-NK cells
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsGene transference
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPersongen Biotherapeutics (Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A